Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8712
Buy Now

Market Overview:

The 7 major menorrhagia markets reached a value of US$ 970 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,380 Million by 2034, exhibiting a growth rate (CAGR) of 3.26% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 970 Million
Market Forecast in 2034
US$ 1,380 Million
Market Growth Rate 2024-2034 3.26%


The menorrhagia market has been comprehensively analyzed in IMARC's new report titled "Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Menorrhagia is a medical term used to describe prolonged or abnormally heavy menstrual bleeding in women. It refers to menstrual periods that involve excessive blood loss, typically exceeding 80 milliliters or lasting longer than seven days. This condition can be distressing and may interfere with a woman's daily activities and quality of life. The common symptoms associated with the ailment include abdominal pain, passing blood clots that are the size of a quarter or bigger, fatigue, weakness, shortness of breath, pale skin, intense cramping, etc. To diagnose menorrhagia, a healthcare provider may review the woman's medical history, conduct a physical examination, and suggest additional tests, such as blood workups, to check for anemia or hormonal imbalances. A transvaginal ultrasound, which involves inserting a probe into the vagina to obtain pictures of the uterus and ovaries to help in identifying structural abnormalities, is also utilized among patients. The doctor may further recommend several diagnostic procedures, including magnetic resonance imaging, hysteroscopy, endometrial biopsy, etc., to rule out other possible causes and validate a diagnosis.

Menorrhagia Market

The rising incidences of hormonal imbalances, particularly between estrogen and progesterone, that can disrupt the normal menstrual cycle and lead to heavy bleeding are primarily driving the menorrhagia market. In addition to this, the increasing prevalence of various associated risk factors, such as the use of intrauterine devices, blood clotting disorders, endometrial polyps, etc., is also bolstering the market growth. Furthermore, the widespread adoption of nonsteroidal anti-inflammatory drugs, including ibuprofen and naproxen sodium, to reduce menstrual bleeding and alleviate pain is acting as another significant growth-inducing factor. Apart from this, the escalating application of minimally invasive endometrial ablation therapy for women who prefer non-hormonal treatment, owing to its numerous advantages, such as rapid recovery time, cost-effectiveness, and improved quality of life, is also creating a positive outlook for the market. Additionally, the emerging popularity of uterine artery embolization techniques for treating this disease condition, since they block the blood flow to the uterus by injecting tiny particles into the uterine arteries, leading to symptom relief, is expected to drive the menorrhagia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the menorrhagia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for menorrhagia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the menorrhagia market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the menorrhagia market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the menorrhagia market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current menorrhagia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Lysteda (Tranexamic acid controlled release) Amring Pharmaceuticals


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the menorrhagia market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the menorrhagia market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the menorrhagia market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of menorrhagia across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of menorrhagia by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of menorrhagia by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with menorrhagia across the seven major markets?
  • What is the size of the menorrhagia patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of menorrhagia?
  • What will be the growth rate of patients across the seven major markets?
     

Menorrhagia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for menorrhagia drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the menorrhagia market?
  • What are the key regulatory events related to the menorrhagia market?
  • What is the structure of clinical trial landscape by status related to the menorrhagia market?
  • What is the structure of clinical trial landscape by phase related to the menorrhagia market?
  • What is the structure of clinical trial landscape by route of administration related to the menorrhagia market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Menorrhagia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More